NEW YORK (GenomeWeb) – Sophia Genetics today announced partnerships in Spain and Greece to accelerate the adoption of next-generation sequencing-based tests.
The Swiss clinical genomics analysis firm has forged deals in Spain with Bioarray, Centro Immunológico de la Comunidad Valenciana, and Genetadi, and has expanded its partnership in Greece with BioAnalytica GenoType.
A Sophia Genetics spokesman said that the company worked with the Spanish labs to help get them validated for clinical NGS-based testing. Sophia Genetics added in a statement that it will now provide "a superior analytical performance solution to diagnose patients faster and more accurately" for some common cancers and inherited conditions such as cystic fibrosis.
The company noted that about 150 clinical labs in Spain perform genetic tests but only about 60 percent of them have adopted NGS technology.
Meanwhile, its deal with BioAnalytica GenoType allows that firm to offer a broad range of NGS-based tests inGreeceat a reduced cost and more quickly, Sophia Genetics added.
Financial and other terms of the deal were not disclosed.
Sophia Genetics' Sophia Data Driven Medicine platform uses machine learning and algorithms for genomic analysis of patient samples. The firm said that DDM is the only solution in Europethat provides full ISO certification and is in compliance with EU data privacy laws.